$SciSparc (SPRC.US)$

Arrayfunction : I think this industry has huge potential; but friendly reminder to folks to use more caution with companies relying on *only* cannabinoids or other psychedelic drug candidates!

Before making a major investment, I highly recommend someone read up on the extra challenges those face in development compared to your standard small-biotech in the country they are working out of. My personal rule of thumb is to double the amount of time you'd except before hitting market.

In the US, trying to do research on anything with or derived from a schedule I classification is an absolute nightmare. Even at the pre-clinical animal level, the red tape explodes exponentially. The overhead  as well as time to completion on every project will balloon due to needing to have the DEA oversight on every step, less choice when it comes to supply chains and needing to take on higher interest rates for company debt.  

Additional liquidity becomes harder too as a good number of grants can't be used for Schedule I research, investors need to balance the bad press risk, and banks are still largely in agreement not to touch Schedule I projecta or products (e.g. why legal dispensaries are almost always cash-based, no banks will take their deposits)

If you are looking for a short swing gain, you are probably okay thinking about the same as small bio-tech since that is going to be more hypetrain than facts. But dangerous to ignore if you are trying to take a long position

Stock_Drift OP Arrayfunction : I trade and invest. Thank you for taking the time here to explain this position. I appreciate it.